文献速递膀胱癌与上尿路尿路上皮癌

膀胱内吉西他滨联合多西他赛治疗未接受卡介苗的非肌层浸润性膀胱尿路上皮癌的2期试验

A Phase 2 Trial of Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guérin‒Naïve Nonmuscle-Invasive Urothelial Carcinoma of the Bladder.
PubMed 文献 · J Urol · 2024-04-23

这项前瞻性单臂开放标签2期试验纳入25例未接受卡介苗的高危非肌层浸润性膀胱尿路上皮癌患者,给予膀胱内吉西他滨联合多西他赛诱导6周后维持治疗2年。3个月完全缓解率为100%,12个月无复发生存率为92%,未见进展至T2期或行根治性膀胱切除术者。

要点

  • 25例未接受卡介苗的高危非肌层浸润性膀胱尿路上皮癌患者中,3个月完全缓解率为100%。
  • 12个月无复发生存率为92%,2例治疗前HGT1患者分别在9和12个月出现HGT1复发。
  • 5例(20%)发生3级不良事件,包括血尿和尿路感染;无进展至T2期或行根治性膀胱切除术者。

核心结论

  • 在这项单臂2期试验中,膀胱内吉西他滨联合多西他赛对未接受卡介苗的高危非肌层浸润性膀胱尿路上皮癌患者耐受良好且疗效令人鼓舞。

研究设计与样本

  • 前瞻性、单臂、开放标签2期试验,纳入未接受卡介苗的高危非肌层浸润性膀胱尿路上皮癌患者。
  • 2020年8月至2022年8月共入组25例患者,中位随访19.6个月。
  • 膀胱内吉西他滨联合多西他赛每周1次共6周诱导,应答者随后每月维持治疗2年。
  • 主要终点为3个月完全缓解,关键次要终点包括不良事件和12个月无复发生存。

主要发现

  • 治疗前病理分期为高级别T1伴原位癌(n=7)、高级别T1不伴原位癌(n=6)、高级别Ta(n=9)和单纯原位癌(n=3)。
  • 3个月完全缓解率为100%,12个月无复发生存率为92%。
  • 2例治疗前高级别T1患者分别在9和12个月出现高级别T1复发。
  • 无患者进展至T2期、行根治性膀胱切除术或出现影像学进展证据。
  • 1级不良事件常见(23/25例),包括血尿、尿频、尿急和乏力;5例(20%)发生3级不良事件,包括血尿和尿路感染。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Combination intravesical gemcitabine and docetaxel (GemDoce) has demonstrated efficacy as second-line therapy for patients with bacillus Calmette-Guérin (BCG)‒unresponsive nonmuscle-invasive urothelial carcinoma of the bladder (NMIBC). In the context of widespread BCG shortages, we performed a phase 2 prospective trial to assess GemDoce for BCG-naïve NMIBC. MATERIALS AND METHODS: This study is a prospective, single-arm, open-label phase 2 trial for patients with BCG-naïve high-risk NMIBC. Intravesical GemDoce was given weekly for 6 weeks as induction followed by monthly maintenance therapy for 2 years among responders. The primary end point was 3-month complete response, and key secondary end points included adverse events (AEs) and 12-month recurrence-free survival. RESULTS: Twenty-five patients were enrolled between August 2020 and August 2022 with median follow-up of 19.6 months. The pretreatment pathologic stages were high-grade (HG) T1 with carcinoma in situ (CIS; n = 7), HGT1 without CIS (n = 6), HGTa (n = 9), and CIS alone (n = 3). The 3-month complete response rate was 100% and recurrence-free survival at 12 months was 92%. Two patients with pretreatment HGT1 had HGT1 recurrences at 9 and 12 months. No patients progressed to T2 disease, underwent radical cystectomy, or had any radiographic evidence of progressive disease. Grade 1 AEs were common (23/25 patients) including hematuria, urinary frequency, urgency, and fatigue. Five patients (20%) experienced a grade 3 AE including hematuria and UTI. CONCLUSIONS: In this single-arm phase 2 trial, GemDoce was well tolerated with promising efficacy for patients with BCG-naïve high-risk NMIBC.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Patel SH, Gabrielson AT, Chan S, et al. A Phase 2 Trial of Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guérin‒Naïve Nonmuscle-Invasive Urothelial Carcinoma of the Bladder. J Urol. 2024. PMID: 38653234. doi:10.1097/JU.0000000000003977

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。